Virginie Rollet-Cohen1, Anne-Laure Roux2, Muriel Le Bourgeois1, Guillaume Sapriel3, Manele El Bahri4, Jean-Philippe Jais4, Beate Heym2, Faiza Mougari5, Laurent Raskine5, Nicolas Véziris6, Jean-Louis Gaillard2, Isabelle Sermet-Gaudelus7. 1. Centre de Ressources et de Compétences pour la Mucoviscidose, Pneumologie et Allergologie Pédiatriques, Hôpital Necker Enfants Malades, Paris, France. 2. UMR 1173, UFR des Sciences de la Santé Simone Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France; Laboratoire de Microbiologie, Hôpital Ambroise Paré, Boulogne, France. 3. UMR 1173, UFR des Sciences de la Santé Simone Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France; Atelier de Bioinformatique, Institut Systématique Evolution Biodiversité, UMR 7205, Paris, France. 4. Département de Biostatistiques, Hôpital Necker Enfants Malades, Paris, France. 5. Laboratoire de Bactériologie, Hôpitaux Lariboisière-Saint Louis, Paris, France; Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Laboratoire de Bactériologie, Hôpitaux Universitaires Pitié-Salpetrière, Paris, France. 6. Sorbonne Université, Centre d'Immunologie et des Maladies Infectieuses, and Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Département de Bactériologie, AP-HP, Hôpitaux Universitaires de l'Est Parisien, Paris, France. 7. Centre de Ressources et de Compétences pour la Mucoviscidose, Pneumologie et Allergologie Pédiatriques, Hôpital Necker Enfants Malades, Paris, France. Electronic address: isabelle.sermet@aphp.fr.
Abstract
BACKGROUND: The cystic fibrosis (CF) pathogen, Mycobacterium abscessus complex, covers three subspecies: M. abscessus, M. massiliense, and M. bolletii. There are no clinical outcome data concerning M. bolletii. Our aim was to characterize M. bolletii lung infections in patients with CF. METHODS: We included patients with M. bolletii lung infection recorded between 1994 and 2012 in France. Data were collected from the CF registry, medical records, and questionnaires submitted to the CF primary physician. Strains were typed by multilocus sequence typing analysis. RESULTS: Fifteen cases were identified in nine CF centers. Nine patients (60%) presented with nontuberculous mycobacterial pulmonary disease. Follow-up of 13 patients showed a trend to more rapid decline in FEV1 in the first year of colonization (-9.4%; SD 19.3) in comparison with noninfected control subjects (-2.3%; SD 12.1) (P = .16). Twelve patients were treated, and 11 received oral macrolides. Treatment-induced eradication occurred in five patients (41.7%). Four patients died (26.7%), including one patient with fatal nontuberculous mycobacterial pulmonary disease. Inducible macrolide resistance was demonstrated in all strains. Patients always harbored unique strains. CONCLUSIONS: Our study reports the largest study cohort of CF patients infected with M. bolletii. M. bolletii infection affects both children and young adults, is most often symptomatic, and may be fatal. Macrolide-based therapies have poor effectiveness. There is no evidence of patient-to-patient transmission.
BACKGROUND: The cystic fibrosis (CF) pathogen, Mycobacterium abscessus complex, covers three subspecies: M. abscessus, M. massiliense, and M. bolletii. There are no clinical outcome data concerning M. bolletii. Our aim was to characterize M. bolletii lung infections in patients with CF. METHODS: We included patients with M. bolletii lung infection recorded between 1994 and 2012 in France. Data were collected from the CF registry, medical records, and questionnaires submitted to the CF primary physician. Strains were typed by multilocus sequence typing analysis. RESULTS: Fifteen cases were identified in nine CF centers. Nine patients (60%) presented with nontuberculous mycobacterial pulmonary disease. Follow-up of 13 patients showed a trend to more rapid decline in FEV1 in the first year of colonization (-9.4%; SD 19.3) in comparison with noninfected control subjects (-2.3%; SD 12.1) (P = .16). Twelve patients were treated, and 11 received oral macrolides. Treatment-induced eradication occurred in five patients (41.7%). Four patientsdied (26.7%), including one patient with fatal nontuberculous mycobacterial pulmonary disease. Inducible macrolide resistance was demonstrated in all strains. Patients always harbored unique strains. CONCLUSIONS: Our study reports the largest study cohort of CF patientsinfected with M. bolletii. M. bolletiiinfection affects both children and young adults, is most often symptomatic, and may be fatal. Macrolide-based therapies have poor effectiveness. There is no evidence of patient-to-patient transmission.
Authors: Salvatore A E Marras; Liang Chen; Elena Shashkina; Rebecca M Davidson; Michael Strong; Charles L Daley; Barry N Kreiswirth Journal: J Clin Microbiol Date: 2021-07-19 Impact factor: 5.948
Authors: Sabrina Cavaglieri Silva; Isabela Neves de Almeida; Wesley Campos Ribeiro; Silvana Spíndola de Miranda; Anna Christina Higino Rocha Journal: Rev Inst Med Trop Sao Paulo Date: 2020-02-07 Impact factor: 1.846